Pfizer
PFE
3,195 hedge funds and large institutions have $197B invested in Pfizer in 2022 Q1 according to their latest regulatory filings, with 158 funds opening new positions, 1,377 increasing their positions, 1,343 reducing their positions, and 183 closing their positions.
3% more repeat investments, than reductions
Existing positions increased: 1,377 | Existing positions reduced: 1,343
0.34% less ownership
Funds ownership: 67.56% → 67.21% (-0.34%)
1% less call options, than puts
Call options by funds: $3.15B | Put options by funds: $3.18B
2% less funds holding
Funds holding: 3,262 → 3,195 (-67)
12% less capital invested
Capital invested by funds: $224B → $197B (-$26.9B)
14% less first-time investments, than exits
New positions opened: 158 | Existing positions closed: 183
33% less funds holding in top 10
Funds holding in top 10: 249 → 166 (-83)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$1.94B |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$716M |
| 3 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$495M |
| 4 |
Los Angeles Capital Management
Los Angeles,
California
|
+$389M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$389M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$1.16B |
| 2 |
Franklin Resources
San Mateo,
California
|
-$923M |
| 3 |
Capital World Investors
Los Angeles,
California
|
-$881M |
| 4 |
Sanders Capital
West Palm Beach,
Florida
|
-$723M |
| 5 |
Coatue Management
New York
|
-$609M |
PFE Hedge Fund Activity: Q1 2022 in Review
3,195 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2022, worth a combined $197B — down 12% from $224B a quarter earlier.
Sellers outnumbered buyers: 183 funds closed out of PFE and 158 opened new positions — a net loss of 25 holders — while 1,343 trimmed existing stakes and 1,377 added.
The largest buyer was Capital International Investors, adding an estimated $1.94B. The largest seller was DZ Bank, cutting an estimated $1.16B.
- 3,195 institutional investors held Pfizer (PFE) as of Q1 2022, down from 3,262 in Q4 2021.
- Funds reported $197B of Pfizer stock for Q1 2022, down 12% quarter-over-quarter.
- 158 funds opened new Pfizer positions in Q1 2022 and 183 closed out, a net change of -25 holders.
- The largest Pfizer buyer in Q1 2022 was Capital International Investors, an estimated $1.94B added.
- The largest Pfizer seller in Q1 2022 was DZ Bank, an estimated $1.16B sold.
Based on aggregated 13F filings for Q1 2022.